Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
Executive Summary
Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.
You may also be interested in...
Drug Use May Shift Under US Medicare Oncology Care Model; Here’s How
‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.
Off-Label Debate Between FDA, Industry To Formally Begin After Election
After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.
FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'
Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.